Information Provided By: 
Fly News Breaks for March 27, 2019
XNCR
Mar 27, 2019 | 07:37 EDT
Berenberg analyst Shanshan Xu initiated Xencor with a Buy and $45 price target saying he sees a turning point ahead following a setback earlier this year due to the partial clinical hold on onf of its CD3 T-cell bispecific antibodies. Xu believes the ramp of Ultomiris royalties and the potential positive data and regulatory approval of MOR-208 will validate Xencor's platform and increase confidence in its broader pipeline, providing a door for further partnerships.
News For XNCR From the Last 2 Days
There are no results for your query XNCR
